Advisory Services Network, LLC Halozyme Therapeutics, Inc. Transaction History

Advisory Services Network, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$33.32 - $42.1 $17,626 - $22,270	529 New	529 $19,000
Q1 2023 May 17, 2023	BUY	$32.86 - $55.7 $9,956 - $16,877	303 Added 50.5%	903 $34,000
Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $24,036 - $35,664	600 New	600 $34,000
Q3 2021 Nov 05, 2021	SELL	$38.47 - $46.42 $615 - $742	-16 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$38.84 - $51.31 $621 - $820	16 New	16 $1,000
Q1 2021 May 24, 2021	SELL	$39.51 - $51.45 $632 - $823	-16 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$25.81 - $43.62 $8,336 - $14,089	-323 Reduced 95.28%	16 $1,000
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $8,725 - $10,044	339 New	339 $9,000
Q4 2019 Feb 04, 2020	SELL	$14.93 - $19.53 $12,123 - $15,858	-812 Closed	0 $0
Q2 2018 Jul 27, 2018	SELL	$16.87 - $20.3 $30,366 - $36,540	-1,800 Reduced 68.91%	812 $14,000
Q1 2018 Apr 23, 2018	SELL	$17.06 - $21.2 $17,060 - $21,200	-1,000 Reduced 27.69%	2,612 $0
Q4 2017 Feb 08, 2018	SELL	$16.75 - $20.8 $36,649 - $45,510	-2,188 Reduced 37.72%	3,612 $73,000
Q3 2017 Oct 12, 2017	BUY	$11.76 - $17.4 $68,208 - $100,919	5,800	5,800 $101,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.